Meeder Asset Management Inc. Purchases New Shares in United Therapeutics Corporation $UTHR

Posted by Stanley Muller on Aug 18th, 2026

Meeder Asset Management Inc. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 9,236 shares of the biotechnology company’s stock, valued at approximately $5,004,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of United Therapeutics in the second quarter valued at $2,868,735,000. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Norges Bank purchased a new position in shares of United Therapeutics during the 4th quarter worth about $293,418,000. Avoro Capital Advisors LLC boosted its stake in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $498.91, for a total transaction of $4,739,645.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $161,867,857.13. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at $23,356,182.60. This represents a 15.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 452,575 shares of company stock valued at $246,248,389. 8.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on UTHR. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday. Royal Bank Of Canada reduced their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Read Our Latest Analysis on UTHR

United Therapeutics Trading Up 1.8%

Shares of UTHR opened at $508.48 on Tuesday. The firm has a market capitalization of $21.81 billion, a P/E ratio of 18.19, a P/E/G ratio of 1.69 and a beta of 0.59. United Therapeutics Corporation has a 12-month low of $302.19 and a 12-month high of $609.35. The firm has a fifty day moving average price of $535.22 and a 200-day moving average price of $536.38.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business posted $6.41 earnings per share. Analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.